These Are 5 Marijuana Stocks Worth More Than $1 Billion

Marijuana stocks are volatile this year. Still, new laws legalizing cannabis mean new markets. As the cannabis industry expands, investors look for steady growth and consistent payoffs to their portfolios. To be a top player, marijuana stocks need to have to a solidified consumer base.

Market capitalization is determined by multiplying the share price by the company’s number of outstanding shares. Unlike share prices, many experts argue that market caps represent a cannabis company’s true worth. Even with a high share price, that price is worthless if there are too many or too little shares on the market. Cannabis stocks with a high market cap are better situated to take on the future of this market because they can guarantee growth for their investors.

These five marijuana stocks have the largest market caps:

Canopy Growth Corporation $6,229,566,067

new TradingView.widget(
{
"width": 770,
"height": 525,
"symbol": "NYSE:CGC",
"interval": "D",
"timezone": "Etc/UTC",
"theme": "Light",
"style": "1",
"locale": "en",
"toolbar_bg": "#f1f3f6",
"enable_publishing": false,
"hide_top_toolbar": true,
"save_image": false,
"container_id": "tradingview_9b99a"
}
);

 

Canopy Growth Corporation (TSX:WEED) (NYSE:CGC) is the largest marijuana stock on this list. With more than $2 billion between them and their closest competition, Canopy could be positioned to profit most from Canadian cannabis legalization in the fall.

[Read More: Marijuana Stock Special Report: Marijuana News Weekly Investor Roundup (August 11)]

Leading up to their epic market cap is their groundbreaking partnership with Constellation Brands (NYSE:STZ). Cannabis-infused beverages and edibles are showing signs of being one of the biggest markets following marijuana legalization. More recent moves also showcase Canopy’s future potential.

The company acquired Canopy Health Innovations earlier this month, including a Canopy Health Animal subsidiary. This strategy could open Canopy up to yet another niche market, which is good news for investors.

Aurora Cannabis Inc. $4,420,192,945

new TradingView.widget(
{
"width": 770,
"height": 525,
"symbol": "TSX:ACB",
"interval": "D",
"timezone": "Etc/UTC",
"theme": "Light",
"style": "1",
"locale": "en",
"toolbar_bg": "#f1f3f6",
"enable_publishing": false,
"hide_top_toolbar": true,
"save_image": false,
"container_id": "tradingview_1b0c1"
}
);

 

Aurora Cannabis (TSX:ACB) (OTCQB:ACBFF) has the second-highest market cap of all marijuana stocks. Their acquisition of MedReleaf earlier this year surely helped, while they are already an established brand in fourteen countries.

But Aurora offers more than marijuana. Aurora designs indoor greenhouse equipment and offers consultation services for designing and construction greenhouses. They use their unprecedented facilities as a blueprint. These moves will no doubt be key to their future successes.

GW Pharmaceuticals $2,306,229,794

new TradingView.widget(
{
"width": 770,
"height": 525,
"symbol": "NASDAQ:GWPH",
"interval": "D",
"timezone": "Etc/UTC",
"theme": "Light",
"style": "1",
"locale": "en",
"toolbar_bg": "#f1f3f6",
"enable_publishing": false,
"hide_top_toolbar": true,
"save_image": false,
"container_id": "tradingview_0ade1"
}
);

 

GW Pharmaceuticals (NASDAQ:GWPH) is the first pharmaceutical company to earn FDA approval for a cannabis-based medicine in the United States. Moreover, they are the only pharmaceutical company on this list.

[Read More: Matt Barnes on Cannabis, Cancer, and Beating Snoop Dogg at Flag Football]

Marijuana stock investors are watching to see when their next drug trials will come in front of the FDA. Currently, they have in their pipeline various cannabis-based drugs in different phases, including treatments for epilepsy and schizophrenia. The future looks like it may just pay off for this pot stock, making them a market cap on which investors should keep an eye.

Aphria Inc. $1,804,932,675

new TradingView.widget(
{
"width": 770,
"height": 525,
"symbol": "TSX:APH",
"interval": "D",
"timezone": "Etc/UTC",
"theme": "Light",
"style": "1",
"locale": "en",
"toolbar_bg": "#f1f3f6",
"enable_publishing": false,
"hide_top_toolbar": true,
"save_image": false,
"container_id": "tradingview_e669e"
}
);

 

PotNetwork reported last week that Aphria Inc. (TSX:APH) was performing better than its competitors in multiple metrics, including production and earnings. It may not give them the highest market cap, but it is a strategy that is catching investor attention.

Mostly because their production price-per-gram remains the lowest in the market. Aphria’s future outlook is definitely optimistic, especially when the company’s expansion is focused on South America and Jamaica. Investors will be watching to see where the chips fall when Aphria finalizes their acquisition of biotech company Scythian.

Cronos Group Inc. $1,054,357,591

new TradingView.widget(
{
"width": 770,
"height": 525,
"symbol": "NASDAQ:CRON",
"interval": "D",
"timezone": "Etc/UTC",
"theme": "Light",
"style": "1",
"locale": "en",
"toolbar_bg": "#f1f3f6",
"enable_publishing": false,
"hide_top_toolbar": true,
"save_image": false,
"container_id": "tradingview_7bcc4"
}
);

 

Rounding out the list of marijuana stocks with the highest market cap is Cronos Group (NASDAQ:CRON). They are the fifth and final pot stock worth over $1 billion, and investors are watching.

The company teamed up with MedMen this year to launch dispensaries in time for Canadian cannabis legalization this fall, a move that makes them even more accessible to the recreational marijuana market. And their exclusive supply agreement with German pharmacy Pohl-Boskamp extends their brand reach into Europe.

It is almost too early to tell what the future will hold for Cronos, but if the company can deliver on their promises, cannabis investors could profit from this pot stock’s growth.

Add comment